Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement
- 5 July 2023
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (9) , 1243-1261
Abstract
Background and Objective Abiraterone is a first-in-class inhibitor of cytochrome P450 17A1 (CYP17A1), and its pharmacokinetic (PK) profile is susceptible to intrinsic and extrinsic variabilities. Potential associations between abiraterone concentrations and pharmacodynamic consequences in prostate cancer may demand further dosage optimization to balance therapeutic outcomes. Consequently, we aim to develop a physiologically based pharmacokinetic (PBPK) model for abiraterone via a middle-out approach to prospectively interrogate the untested, albeit clinically relevant, scenarios. Methods To characterize in vivo hydrolysis of prodrug abiraterone acetate (AA) and supersaturation of abiraterone, in vitro aqueous solubility data, biorelevant measurements, and supersaturation and precipitation parameters were utilized for mechanistic absorption simulation. CYP3A4-mediated N-oxidation and sulfotransferase 2A1-catalyzed sulfation of abiraterone were subsequently quantified in human liver subcellular systems. Iterative PBPK model refinement involved evaluation of potential organic anion transporting polypeptide (OATP)-mediated abiraterone uptake in transfected cells in the absence and presence of albumin. Results The developed PBPK model recapitulated the duodenal concentration–time profile of both AA and abiraterone after simulated AA administration. Our findings established abiraterone as a substrate of hepatic OATP1B3 to recapitulate its unbound metabolic intrinsic clearance. Further consideration of a transporter-induced protein-binding shift established accurate translational scaling factors and extrapolated the sinusoidal uptake process. Subsequent simulations effectively predicted the PK of abiraterone upon single and multiple dosing. Conclusion Our systematic development of the abiraterone PBPK model has demonstrated its application for the prospective interrogation of the individual or combined influences of potential interindividual variabilities influencing the systemic exposure of abiraterone.Keywords
Funding Information
- Singapore Ministry of Education Tier 1 Academic Research Funding (R-148-000-249-114)
- National University of Singapore (NUS) President’s Graduate Fellowship
- National University of Singapore, Department of Pharmacy, Final Year Project Funding
This publication has 36 references indexed in Scilit:
- Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo ObservationsDrug Metabolism and Disposition, 2014
- Impact on abiraterone pharmacokinetics and safety: Open‐label drug–drug interaction studies with ketoconazole and rifampicinClinical Pharmacology in Drug Development, 2014
- Single‐dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairmentThe Journal of Clinical Pharmacology, 2014
- A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjectsXenobiotica, 2012
- Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancerCancer Chemotherapy and Pharmacology, 2012
- Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy menCancer Chemotherapy and Pharmacology, 2012
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterionsJournal of Pharmaceutical Sciences, 2006
- Transverse Movement of Spin–Labeled Phospholipids in the Plasma Membrane of A Hepatocytic Cell Line (Hepg2): Implications for Biliary Lipid SecretionHepatology, 1996
- Transverse movement of spin-labeled phospholipids in the plasma membrane of a hepatocytic cell line (HepG2): Implications for biliary lipid secretionHepatology, 1996